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Summary The therapeutic efficacy of gemcitabine, a new nucleoside analogue, was assessed in a variety of
well-established human soft tissue sarcoma and ovarian cancer xenografts grown s.c. in nude mice. Tumour
lines selected had different histological subtypes, growth rates and sensitivities to conventional cytostatic
agents. The three different doses and schedules designed on the basis of a mean weight loss between 5% and
15% were i.p. injections of daily 3.5 mg kg-' x 4, every 3 days 120 mg kg-' x 4, and weekly 240 mg kg-' x 2,
which ultimately resulted in 19%, 10% and 4% toxic deaths, respectively. The weekly schedule induced
> 50% growth inhibition in 2/4 soft tissue sarcoma and 4/6 ovarian cancer lines, while in three ovarian cancer
lines > 75% growth inhibition was obtained. The anti-tumour effects ofgemcitabine appeared to be similar or
even better than previous data with conventional drugs tested in the same tumour lines. In comparison with
the every 3 days schedule, the weekly and the daily schedule were less effective in 5/7 and 3/3 tumour lines
(P<0.001), respectively. In another experiment in three human tumour lines selected for their differential
sensitivity to gemcitabine, weekly injections of 240 mg kg-' x 6 did not result in a significant increase in the
percentages of growth inhibition when compared to lower doses of 120 mg kg-' or 60 mgkg-' in the same
schedule. However, the 240 mg kg-' weekly x 6 schedule showed superior effects in 2/3 tumour lines in
comparison with the same dose given every 2 weeks x 3 (P< 0.05). The preclinical activity of gemcitabine
suggests that the drug can induce responses in soft tissue sarcoma and ovarian cancer patients. Our results
further indicate that clinical trials of gemcitabine in solid tumour types should be designed on the basis of a
schedule rather than a dose dependence.
In the search for new anti-cancer agents, gemcitabine (2',2'-
difluorodeoxycytidine, dFdC) has recently emerged from the
preclinical drug development stage as a promising candidate
for the treatment of non-haemotological malignancies. Gem-
citabine is a new antimetabolite active against human
leukaemic cell lines in vitro and a number of solid murine
and human tumours in mice (Hertel et al., 1990; Braakhuis et
al., 1991). The preclinical activity of gemcitabine was more
pronounced than that of the nucleoside analogue 1-0-D-
arabinofuranosylcytosine (ara-C), a drug commonly used in
the treatment of adult acute leukaemia. Both drugs inhibit
cellular proliferation in S phase and cause cells to accumulate
in the G1-S phase (Hertel et al., 1990). The apparent
similarities in the molecular structures and the reversal of
cytotoxicity by deoxycytidine led to comparative studies on
the metabolic and pharmacokinetic characteristics of gem-
citabine and ara-C (Heinemann et al., 1988). It was found in
Chinese hamster ovary cells, that the cellular concentration
of the 5'-triphosphate of gemcitabine (dFdCTP) was 20-fold
greater than that observed for ara-CTP at equimolar concen-
trations of the drugs. These differences in cellular accumula-
tion of the respective triphosphates were due to an increased
membrane transport, a higher deoxycytidine kinase affinity,
and a longer retention of the intracellular 5'-triphosphate for
gemcitabine relative to ara-C. The favourable characteristics
of gemcitabine were the reason to introduce the drug into
clinical trials (Abbruzzese et al., 1991; Grunewald et al.,
1992).
The preclinical in vivo analysis of the anti-tumour efficacy
of gemcitabine was first carried out in a variety of the
well-known murine and human tumour systems (Hertel et al.,
1990). On the basis of a significant reduction in growth and
cures in xenografts derived from squamous cell carcinoma
tissue of the head and neck region, Braakhuis et al. (1991)
suggested the drug of potential value in the treatment of
head and neck cancer patients. In order to obtain further
insight into the possible activity of gemcitabine against other
malignancies, we extended the preclinical in vivo anti-tumour
screening of gemcitabine in human tumour xenografts
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selected from two panels of well-defined human soft tissue
sarcoma and ovarian cancer lines. In the experiments, we put emphasis on the influence of the schedule and the dose of
gemcitabine to reach optimal growth inhibition.
Materials and methods
Animals and tumour lines
Female NMRI/Cpb nude mice (Harlan Cpb, Zeist, The
Netherlands) were maintained in filter-top cages under con-
trolled atmospheric conditions. Cages, covers, food, bedding
and water were sterilised and changed once a week. Animal
handling was done in a laminar down-flow hood.
Tumour lines were selected from a panel of ten human soft
tissue xenografts and 15 human ovarian cancer xenografts on
the basis of differences in histological subtype and growth
rate, as well as their sensitivity to equitoxic doses of conven-
tional cytostatic agents. Most characteristics mentioned in
Table I have been described previously (Winograd et al.,
1987; Boven et al., 1989; Molthoff et al., 1991). Tumour lines
were maintained by serial subcutaneous (s.c.) transplantation
of tumour fragments of 2-3 mm in diameter in both flanks
of 8- to 10-week-old animals.
Treatment andevaluation
Gemcitabine (Lilly Research Centre Limited) was provided
as a powder and was dissolved in NaCl 0.9% to reach a final
concentration of 10mgml-. In the first step of the experi-
ment the drug was injected i.p. in various schedules to deter-
mine equitoxic doses. At these doses, the mice were required
to lose between 5% and 15% of the initial weight within 2
weeks after the first injection. The equitoxic doses were
assessed in non-tumour-bearing mice first and adjusted in
tumour-bearing mice, if indicated. Thereafter, the efficacy of
gemcitabine was determined in tumour-bearing mice with the
use of three different doses and schedules.
Xenografts were measured once or twice (for A2780) a
week in three dimensions with a vernier caliper by the same
observer. The volume was calculated by the equation
length x width x height x 0.5, and expressed in mm3. At the
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Table I Characteristics of human tumour lines grown s.c. in nude mice
Growth inhibitionb
Tumour line Histology TDa CDDPc CTX DOX GEM
Soft tissue sarcoma
S.Ho Malignant fibrous histiocytoma 16 n.d.d + + _ +
S.La(C) Malignant fibrous histiocytoma 11 n.d. - - +
S.Hu Leiomyosarcoma 12 n.d.
S.To Synovial cell sarcoma 13 n.d.
Ovarian cancer
Ov.Pe Moderately differentiated mucinous 8 - + + + +
Ov.He Moderately differentiated mucinous 9 - - + +
OVCAR-3 Poorly differentiated serous 8 + + + - + +
A2780 Undifferentiated 3.5 + + + + + + +
FKo Moderately differentiated serous 12
Ov.Ri(C) Moderately differentiated serous 11 + + + +
aMeanvolumedoublingtimeindays. b< 50%(_); > 50% <75% (+); > 75% (+ +).CCDDP,
cisplatin 5mgkg-' i.v. q7dx2; CTX, cyclophosphamide 150mgkg-' i.p. ql4dx2; DOX,
doxorubicin 8 mg kg-' i.v. q7dx2; gemcitabine 240mg kg-' i.p. q7dx2. dn.d., not determined.
start of treatment (day 0), groups of 5-7 tumour-bearing
mice were formed to provide 8-14 tumours with a mean
volume of 50-150 mm3 in each group. Deaths occurring
within 2 weeks after the final injection were considered toxic
deaths; these animals were excluded from the study.
For evaluation of drug efficacy, the tumour volumes were
converted to values related to the initial tumour volume. This
relative tumour volume was expressed by the formula VT/VO,
where VT is the value at any given day and V0 the volume at
the start of treatment. The ratio of the mean relative volume
of treated tumours over that of control tumours multiplied
by 100% (T/C%) was assessed on each day of measurement.
From the lowest T/C% obtained within 5 weeks after the last
day of injection growth inhibition (100%-T/C%) was cal-
culated to express drug efficacy. Complete remissions were
defined as the total disappearance of tumours without re-
growth in the following month. Differences of significance
between the anti-tumour effects of particular treatment
regimens were determined by means of Student's t-test.
Results
Doses and schedules
The equitoxic doses of gemcitabine were based on the induc-
tion of a mean weight loss between 5% and 15% and were
determined for daily x 5, every 3 days x 4, and weekly x 2
i.p. injections in non-tumour-bearing animals first. Starting
doses were derived from previous experiments carried out by
other investigators (Hertel et al., 1990; Braakhuis et al.,
1991). Doses of 10mg kg-', 5 mg kg-', and 2.5 mg kg-l were
administered for daily injections, but proved to be too toxic
(mean weight loss >20%) for doses of >5 mg kg-'. Further
adjustment of the dose in steps of 4 mgkg', 3.5 mg kg-'
and 3mgkg-' led to a mean weight loss of >20%, 11%
(s.d. ± 1%), and 7% (s.d. ± 3%), respectively. The schedule
of 3.5 mg kg-' i.p. daily x 5 was selected, but a mean weight
loss >20% in tumour-bearing animals necessitated a reduc-
tion of 1 day. For the every 3 days x 4 schedule a dose of
120 mgkg-' was used, which was determined to be the
optimal dose in the same strain of mice by Braakhuis et al.
(1991). In fact, increasing this dose to 140 mg kg' in non-
tumour-bearing animals resulted in a mean weight loss
>20%. For weekly x 2 injections a dose range of 120 mg
kg- with increases in steps of 40 mg kg-l up to 280 mg kg-'
was tested. Doses of 240 mg kg-' and 280 mg kg-' led to a
mean weight loss of 6% (s.d. ± 7%) and 13% (s.d. ± 3%),
respectively, while lower doses did not induce loss of weight.
Because of additional weight loss to be expected in tumour-
bearing animals, the weekly dose of 240 mg kg-' was
selected.
In the treatment experiments animals were weighed only at
the time of the injections or the weekly tumour measure-
ments. Mean weight loss was calculated within 2 weeks after
the first injection in non-lethal mice (Table II). Except for
toxic deaths, recovery from weight loss was rapid and
invariably reversible within 1 week after treatment. Thus,
mean weight loss for the weekly schedule depicted in Table II
does not reflect the maximum weight loss to be expected, if
Table II Growth inhibition induced by gemcitabine administered i.p. at the maximum tolerated dose in various schedules
Tumour 3.5 mgkg-I daily x 4 120mgkg-' every 3 days x 4 240mgkg- weekly x 2
line GI% (day)a wLb TDc GI% (day) WL TD GI% (day) WL TD
Soft tissue
S.Ho 52%d (13) 2% ± 2% 2/6
S.La(C) 47%d (28) 5% ± 2% 0/6 86%de (28) 4% ± 2% 0.6
S.La(C) 23% (31) 26% ± 2% 4/6 89%d,e (31) 9% ± 6% 0/6 74%d (31) 3% ± 4% 0/6
S.Hu 27% (35) 3% ± 7% 0/6
S.Hu 54%d (32) 14% ± 5% 1/7 89%dcf (32) 7% ± 6% 1/7 49%d (32) 5% ± 6% 0/7
S.To 10% (36) 0% ± 3% 0/6
S.To 17% (20) 13% ± 14% 0/6 23% (20) 0% ± 2% 0/6
Ovary
Ov.Pe 82%d (30) 5% ± 3% 0/6
Ov.Pe 61%d (33) 9% ± 6% 0/7 77%d,e,f (33) 9% ± 7% 0.7 70%d (33) 0% ± 3% 0/7
Ov.He 84%d,f (35) 15% ± 12% 3/6 64%d (28) 5% ± 3% 0/6
OVCAR-3 98%d,f (27) 14% ± 10% 1/6 92%d (20) 0% ± 4% 0/6
A2780 99%df (27) 19% ± 8% 0/6 98%d (18) 16% ± 6% 0/6
FKo 11% (39) 6% ± 5% 1/6
Ov.Ri(C) 36% (28) 1%± 3% 0/6
aGI, growth inhibition (%) and optimal dayofmeasurement.bWL, weight loss (% ± s.d.) within 2 weeks after thefirst injection.CTD, toxicdeath
within 2 weeks after the final injection. dSignificantly different from control tumours, P<0.001. 1120 mgkg-' i.p. given every 3 days x 4 shows
significantly superior growth inhibition to 3.5 mg kg-' i.p. daily x 4, P<0.001. fl20 mg kg-' i.p. givenevery 3 days x 4 showssignificantlysuperior
growth inhibition to 240mg kg-' i.p. weekly x 2, P<0.001.
5354 E. BOVEN et al.
animals had been weighed more often. As an example, mice
bearing A2780 xenografts were weighed twice-a-week and
mean weight loss recorded was 16% (s.d. ± 6%), which illu-
strates the equal toxicity of the weekly schedule. For the
every 3 days schedule and the daily schedule mean weight
loss varied for the mice bearing different human tumour lines
and was, in general, in the range between 5% and 15% of
the initial weight. With reference to toxic deaths (Table II)
the weekly schedule appeared to be the least toxic as 4% of
animals died, followed by 10% toxic deaths in the every 3
days schedule. Using the daily schedule, 19% of animals died
from toxicity.
Influence ofschedule
Gemcitabine at equitoxic doses was administered in three
schedules (Table II). The weekly schedule of 240 mg kg- x 2
was studied in all human tumour lines. Growth inhibition of
>,50% was obtained in 2/4 soft tissue sarcoma xenografts
and 4/6 ovarian cancer xenografts. In Ov.Pe, OVCAR-3
and A2780 xenografts >75% inhibition of growth could be
measured. In comparison with previous experiments with
conventional cytostatic agents (Table I), gemcitabine ap-
peared slightly more effective than doxorubicin in S.Ho
xenografts and than doxorubicin and cyclophosphamide in
S.La(C) xenografts. In Ov.Pe xenografts, gemcitabine was
superior to cisplatin, cyclophosphamide and doxorubicin, but
the reverse was observed in Ov.Ri(C) xenografts. The percen-
tages of growth inhibition of gemcitabine calculated in
Ov.He, OVCAR-3 and A2780 xenografts were similar to or
better than the data for the three conventional agents.
Against S.Hu, S.To and FKo xenografts the clinically known
compounds were inactive, as was gemcitabine.
The weekly schedule of gemcitabine was compared to the
every 3 days schedule of 120 mg kg-' x 4 in seven human
tumour lines (Table II). In five of these, the every 3 days
schedule was significantly more effective (P<0.001). With
this schedule, 4/11 complete remissions could be obtained in
A2780 xenografts. The anti-tumour effects reached with the
weekly schedule were not significantly different from the
extent of growth inhibition observed after the administration
of 3.5 mg kg-' daily x 4. Again, the every 3 days schedule
was significantly more effective than the daily schedule
(P<0.001) in S.La(C), S.Hu and Ov.Pe xenografts. Figure 1
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Figure 1 Treatment results of gemcitabine administered i.p. at the maximum tolerated dose of 240 mg kg- weekly x 2,
120 mg kg-' every 3 days x 4, or 3.5 mg kg-' daily x4 (----) in three human tumour xenografts as compared to control
tumours ( ). The relative tumour volume is the tumour volume at any given day VT/the volume at the start of treatment V0.
The graphs were drawn from the mean ( ± s.e.m.) of the relative tumour volumes.
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visualises the superior efficacy of the every 3 days schedule
compared to the weekly and the daily schedule in S.La(C),
S.Hu and Ov.Pe xenografts.
Influence ofdose
Three human tumour lines with a variable degree of sen-
sitivity to the weekly x 2 schedule of gemcitabine, S.La(C),
S.Hu and Ov.Pe, were selected to study the presence of a
possible relationship between the dose and the response to
the drug. Tumour-bearing mice were treated for 6 weeks with
weekly injections of 240 mg kg-', 120 mg kg- or 60 mg kg-
and another group of animals was treated with 2-weekly
injections of 240 mg kg- '. In Figure 2 it is shown, that
gemcitabine resulted in the reduction of tumour volume in
S.La(C) xenografts, in stabilisation of tumour growth in
Ov.Pe xenografts, while in S.Hu xenografts limited growth
delay was obtained. The anti-tumour effects of the various
doses expressed in percentages of growth inhibition (Table
III) were not greatly different. The 240 mg kg-' weekly x 6
schedule showed superior effects only in S.La(C) and S.Hu
xenografts when compared to the same dose given every 2
weeks x 3, but the difference hardly reached the level of
significance (P<0.05). However, in S.La(C) xenografts the
number of complete remissions was highest for the 240 mg
kg- x 6 schedule (9/10), followed by 120mg kg' x 6 and
60 mg kg-l x 6 (in both schedules 6/10) and the 240 mg kg-'
2-weekly x 3 schedule (4/8).
Discussion
For ara-C in the treatment of adult acute leukaemia patients
it has been recognised, that drug efficacy is related to the
schedule of administration, where a continuous infusion will
induce a higher response rate than daily conventional doses
over periods of 5-10 days (Freireich, 1987). Gemcitabine
also shows a schedule dependence. In our experiments we
demonstrated, that the slightly more toxic daily schedule was
less effective than the every 3 days schedule. A similar
experience was reported by Hertel et al. (1990) in L1210
leukaemia. In addition we found, that the longer interval of 1
week between the injections will again result in a lower
degree of growth inhibition. The clinical relevance of this
finding is not yet known. In the various phase II trials
presently underway a weekly schedule is being used consist-
ing of treatment for 3 weeks followed by 1 week's rest
(Lund et al., 1993). Similar to the large differences in the
administered doses per schedule in mice, patients can
tolerate a considerably higher weekly dose of gemcitabine
(the dose recommended for phase II trials is 1000mgm-2)
than a daily dose of the drug (recommended dose 9 mg m-2),
while in a 2-weekly schedule a dose of 4560 mg m-2 was well
tolerated.
The low dose-response relationship for gemcitabine found
in our human tumour lines may be explained by the cellular
pharmacology of the drug. Phosphorylation by deoxycytidine
kinase is required to induce cytotoxicity upon incorporation
of dFdCTP into DNA. Inactivation of phosphorylated gem-
citabine is caused by deamination to difluorouridine, a reac-
tion catalysed by deoxycytidine deaminase (Heinemann et al.,
1988; Gandhi & Plunkett, 1990). In phase I clinical trials,
100
10
0.1
100
0
E
4
4-
G
10
100
10
1
0.1
-1
S.Hu
. . T 'T T. T . .. .. .
0
Ov.Pe
. T . .
0 10 20 30 40 50 60 70 80
Days after initial treatment
Figure 2 Treatment results of gemcitabine administered i.p. at
the maximum tolerated dose of 240 mg kg-' weekly x 6 (v), and
lower doses of 120mg kg-' weekly x 6 (U), 60mgkg-' week-
ly x 6 (A), or 240 mgkg-' 2-weekly x 3 (*), as compared to
control tumours (@). The relative tumour volume is the tumour
volume at any given day VT/the volume at the start of treatment
V0. The graphs were drawn from the mean of the relative tumour
volumes.
Table III Growth inhibition induced by gemcitabine administered i.p. weekly or
2-weekly in various doses
Tumour 60mgkg-' 120 mgkg-' 240 mgkg-' 240mgkg-'
line Day' weekly x 6 weekly x 6 weekly x 6 2-weekly x 3
S.La(C) 49 96.8% 99.4% 99.8%b 83%
S.Hu 49 55% 65% 65%b 42%
Ov.Pe 50 66% 72% 72% 65%
aDay ofmeasurement. b240 mgkg-' i.p. weekly x 6 shows significantly superior
growth inhibition to 240 mgkg-' i.p. 2-weekly x 3, P<0.05.
1
- n1 I156 E. BOVEN et al.
Grunewald et al. (1990, 1991, 1992) have shown that the
accumulation rate of dFdCTP in both leukaemia and
mononuclear cells is saturated at certain plasma or intracel-
lular drug levels. At higher gemcitabine doses, no further
increase or even a decreased value of dFdCTP could be
measured. Our experiments suggest, that the phosphorylation
of gemcitabine in tumour cells is also a saturable process.
Further pharmacodynamic analysis of the intracellular
metabolism of gemcitabine will clarify the precise mechanism
of action and the variation in cytotoxicity between tumour
cells.
If a relationship exists between the ability to accumulate
and retain dFdCTP and the response, as has been demon-
strated for high-dose continuous infusion of ara-C (Estey et
al., 1990), it is anticipated that in S.La(C) xenografts a higher
area under the concentration-times-time curve (AUC) for
dFdCTP can be reached when compared to S.Hu xenografts.
In patients, the AUC of dFdCTP in mononuclear cells
indeed augmented with prolonged administration of gem-
citabine at a dose maintaining maximal dFdCTP accumula-
tion (Grunewald et al., 1991). In tumour cells exposed to
gemcitabine in vitro, dFdCTP accumulation was clearly dem-
onstrated to be time dependent (Ruiz van Haperen et al.,
1991). Whether longer infusion periods will result in higher
anti-tumour efficacy rather than increased side-effects in
patients has yet to be determined.
In our laboratory we have found a good correlation
between clinical data from phase II trials and the chemosen-
sitivity of the panels of human soft tissue sarcoma xenografts
and human ovarian cancer xenografts, both for conventional
cytostatic agents and their analogues (Boven et al., 1985;
Winograd et al., 1987; Boven, 1988; Boven et al., 1989;
Boven et al., 1990; Boven, 1991). The validity of the xeno-
graft model has not yet been proven for all classes of anti-
tumour agents, such as antimetabolites. On one hand,
pharmacological differences between mouse and man may
specifically be responsible for a negative correlation. As
examples, mice can tolerate much lower doses of methotrex-
ate and 5-fluorouracil relative to maximum doses in patients,
which may be the reason that these drugs have low or no
efficacy in head and neck cancer xenografts (Braakhuis et al.,
1983) and colon cancer xenografts (Mattern et al., 1988),
respectively. On the other hand, a higher proportion of
rapidly proliferating tumour cells in the log-phase of growth
in xenografts as compared to patients' tumours may
theoretically result in an increased susceptibility to the
cytotoxicity of other antimetabolites, as may be the case for
gemcitabine. However it appears, that the xenograft model
can indeed predict clinical activity of gemcitabine in parti-
cular solid tumour types. Objective responses have been
noted in a variety of malignancies, including non-small cell
lung cancer, ovarian cancer and breast cancer patients (Lund
et al., 1993).
In conclusion, gemcitabine is a new nucleoside analogue
with a unique mechanism of action, which should be inves-
tigated further for a rational design of clinical trials. Pre-
clinical analysis of the anti-tumour activity against human
tumour xenografts suggests, that the drug may be effective in
soft tissue sarcoma and ovarian cancer patients.
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